On Wednesday, August 19, 2009, fourteen academics from the U.S., Canada and the UK were joined by select PhRMA staff to participate in a PhRMA International Alliance Development Academic Roundtable. The discussion focused on the issues of biosimilars, also referred to as follow-on biologics (FOBs), health technology assessment (HTA), and intellectual property protection. Summary Report